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Background: Oct4 is a major transcription factor related to stem cell self-renewal and differentiation. To fulfill its
functions, it must be able to enter the nucleus and remain there to affect transcription. KPNA2, a member of the
karyopherin family, plays a central role in nucleocytoplasmic transport. The objective of the current study was to
examine the association between Oct4 and KPNA2 expression levels with regard to both the clinicopathological
characteristics and prognoses of patients with non-small-cell lung cancer (NSCLC).
Methods: Immunohistochemistry was used to detect the expression profile of Oct4 and KPNA2 in NSCLC tissues
and adjacent noncancerous lung tissues. Real-time polymerase chain reaction and western blotting were used to
detect the mRNA and protein expression profiles of Oct4 and KPNA2 in lung cancer cell lines. Small interfering
RNAs were used to deplete Oct4 and KPNA2 expressions. Double immunofluorescence was used to detect Oct4
expression in KPNA2 knockdown cells. Co-immunoprecipitation was used to detect the interaction of Oct4 and
KPNA2.
Results: Oct4 was overexpressed in 29 of 102 (28.4%) human lung cancer samples and correlated with
differentiation (P = 0.002) and TNM stage (P = 0.003). KPNA2 was overexpressed in 56 of 102 (54.9%) human lung
cancer samples and correlated with histology (P = 0.001) and differentiation (P = 0.045). Importantly, Oct4 and
KPNA2 expression levels correlated significantly (P < 0.01). Expression of Oct4 and KPNA2 was associated with short
overall survival. In addition, depleting Oct4 and KPNA2 expression using small interfering RNAs inhibited
proliferation in lung cancer cell lines. Real-time polymerase chain reaction and western blotting analysis indicated
that reduction of KPNA2 expression significantly reduced mRNA and nucleoprotein levels of Oct4. Double
immunofluorescence analysis revealed that nuclear Oct4 signals were reduced significantly in KPNA2 knockdown
cells. Co-immunoprecipitation experiments revealed that KPNA2 interacts with Oct4 in lung cancer cell lines.
Conclusion: Oct4 and KPNA2 play an important role in NSCLC progression. Oct4 nuclear localization may be
mediated by its interaction with KPNA2.
Keywords: Non-small-cell lung cancer, Oct4, KPNA2, Nucleocytoplasmic transportBackground
Oct4, also known as POU5F1 (POU domain, class 5, tran-
scription factor 1), is encoded by the POU5F1 gene in
humans [1]. It is a homeodomain transcription factor of
the POU family. Oct4 is normally found in totipotent or
pluripotent stem cells of pregastrulation embryos and is es-
sential to maintain their self-renewal [2]. Downregulation
of Oct4 results in loss of stem cells [3]. The Oct4 transcrip-
tion factor can be considered a master regulator of* Correspondence: xinshanjia@126.com
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reproduction in any medium, provided the ormaintenance and differentiation in pluripotent cells. Previ-
ous studies have indicated an involvement of Oct4 in
tumorigenicity and malignancy of lung cancers [4]. Oct4
might be a biomarker for assessing the prognosis of hepa-
tocellular carcinoma and gastric cancer [5,6]. For patients
with hypopharyngeal squamous cell carcinoma, Oct4 ex-
pression is an independent predictive factor [7]. Oct4 ex-
pression has also been observed in human breast cancer
stem-like cells, suggesting an involvement in self-renewal
and tumorigenesis [8]. Three isoforms of Oct4 have been
identified – Oct4A, Oct4B, and Oct4B1. Oct4A is primarily
localized in the nucleus, whereas Oct4B and Oct4B1his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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has been proven to regulate pluripotency [9].
Transcription factors need to enter and remain in the
nucleus to fulfill their functions. The Oct4 transcription
factor homeodomain signature structure is important for
both DNA binding and nucleocytoplasmic trafficking
[10,11]. The importin transport system provides the ma-
chinery for nucleocytoplasmic transport. Nuclear protein
transport is a complex process and aberrant expression
of nuclear transport factors may result in profound de-
regulation of gene transcription [12]. KPNA2 (importin
α1), a member of the karyopherin (importin) family,
plays a central role in nucleocytoplasmic transport [13].
Together with importin-β, the KPNA2-bound cargo pro-
tein forms a ternary complex, which interacts with the
nuclear pore complex and translocates into the nucleus,
guided by a nuclear localization signal [14]. A previous
study showed that KPNA2 is mainly expressed in undiffer-
entiated embryonic stem (ES) cells, and nuclear import of
Oct4 is mediated by KPNA2 in mouse ES cells during dif-
ferentiation into neurons [15]. Oct4 and KPNA2 are
reported to have a strong interaction in ES cells [16]. In
addition, KPNA2 was identified as a potential biomarkerTable 1 The expression of Oct4 and KPNA2 and their relation
Features No. Nuclear Oct4 immunor
Negative Positive (%)
Age (years)
<60 50 36(72.0) 14(28.0)
≥60 52 37(71.2) 15(28.8)
Gender
Male 59 42(71.2) 17(28.8)
Female 43 31(72.1) 12(27.9)
Smoke
Yes 52 36(69.2) 16(30.8)
No 50 37(74.0) 13(26.0)
Histology
Adenocarcinoma 60 41(68.3) 19(31.7)
Squamous cell 42 32(72.6) 10(23.8)
Carcinoma
Differentiation
Well 38 34(89.5) 4(10.5)
Moderate-Poor 64 39(60.9) 25(39.1)
TNM stage
I/II 55 46(83.6) 9(16.4)
III/IV 47 27(57.4) 20(42.6)
Angiolymphatic invasion
No 57 44(77.2) 13(22.8)
Yes 45 29(64.4) 16(35.6)
*P < 0.05.for non-small-cell lung cancer (NSCLC) by integration of
the cancer cell secretome and tissue transcriptome [17].
For lung cancer, however, very few reports have men-
tioned the two genes. This current study provides direct
evidence for the interaction between Oct4 and KPNA2
and demonstrates that KPNA2 may contribute to Oct4
nuclear translocation in lung cancer.
Methods
Patient populations and clinical specimens
The Ethics Committee of the China Medical University
approved this study. One hundred and two NSCLC sam-
ples and the corresponding normal lung tissues were
obtained from the First Affiliated Hospital of China Med-
ical University during 2004–2007. Tissues were formalin
fixed and paraffin embedded. Before the operation, the pa-
tients had not received chemotherapy or radiotherapy.
Histological types and differentiation degrees were catego-
rized by the 2004 WHO standards, and TNM were classi-
fied according to the 2009 UICC TNM classification.
Relevant clinical and pathological features (Table 1) were
obtained from the patients’ files and/or by telephone inter-
views with the patient or their relatives.ships with clinicopathological characteristics
eactivity Nuclear KPNA2 immunoreactivity
P Negative Positive (%) P
0.925 25(50.0) 25(50.0) 0.329
21(40.4) 31(59.6)
0.920 28(47.5) 31(52.5) 0.574
18(41.9) 25(58.1)
0.593 22(42.3) 30(57.7) 0.563
24(48.0) 26(52.0)
0.387 35(58.3) 25(41.7) 0.001*
11(26.2) 31(73.8)
0.002* 22(57.9) 16(42.1) 0.045*
24(37.5) 40(62.5)
0.003* 29(52.7) 26(47.3) 0.093
17(36.2) 30(63.8)
0.156 25(43.9) 32(56.1) 0.777
21(46.7) 24(53.3)
Figure 1 (See legend on next page.)
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Figure 1 Expression of Oct4 and KPNA2. Immunohistochemical staining for Oct4 and KPNA2 expression in cancerous tissues and their
corresponding paracancerous tissues. Brown grains represent a positive signal. The positive expression site of Oct4 and KPNA2 was mainly in the
nucleus of tumor cells. Oct4 negative expression in paracancerous tissue (Para) (A); Oct4 positive expression in lung adenocarcinoma (Ad) (B) and
lung squamous cell carcinoma (SCC) (C); KPNA2 negative expression in Para (D); KPNA2 positive expression in lung Ad (E) and lung SCC (F).
Western blot analysis of the expression of Oct4 and KPNA2 in lung Ad, lung SCC, and Para (G). Each bar represents the mean ± SD of three
independent experiments. *P < 0.05, **P < 0.01. Immunohistochemical staining for Oct4 (H) and KPNA2 (I) in a case of lung SCC.
Immunohistochemical staining for Oct4 (J) and KPNA2 (K) in a case of lung Ad. Original magnification, 400 × .
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The paraffin-embedded tissues were cut into 5-μm sec-
tions, placed on slides, and baked at 60°C for 120 min. The
sections were de-paraffinized with xylenes and rehydrated.
They were subjected to heat-induced antigen retrieval
using citrate buffer (10 mM, pH 6.0) in a pressure cooker
for 2 min and then cooled to room temperature for
20 min. The sections were treated with 3% hydrogen per-
oxide in methanol to quench the endogenous peroxidase
activity, followed by incubation with normal serum to block
nonspecific binding. The slides were then incubated with
an anti-Oct4 antibody (1:100) (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA) and an anti-KPNA2 antibody
(1:100) (Santa Cruz Biotechnology) overnight at 4°C,
respectively. As a negative control for the staining pro-
cedure, the primary antibody was replaced with PBS.
The second antibody was from an SP reagent kit
(Zhongshan Biotechnology Company, Beijing, China).
After washing, the tissue sections were treated with a
biotinylated anti-mouse second antibody, followed by further
incubation with streptavidin-horseradish peroxidase complex
for 15 min. The sections were stained with diaminobenzidine
and then counterstained with hematoxylin. The stained
slides were reviewed and scored independently by two pa-
thologists. The proportion (0: none; 1: < 25%; 2: 25–50%; 3:
51–75%; and 4: > 75%) and intensity (0, none; 1, weak;
2, intermediate; and 3, strong) scores were added to
obtain a total score, which ranged from 0 to 7. Specimens
were categorized into one of two groups according to
their overall scores: (1) negative expression, < 4 points;
(2) positive expression, 4–7 points.Table 2 Oct4 and KPNA2 expression cross tabulation
KPNA2 Oct4 Total
Negative(%) Positive(%)
negative 43(93.5) 3(6.5) 46
positive 30(53.6) 26(46.4) 56
Total 73 29 102
P < 0.01.Cell culture
Human lung cancer cell lines A549, LTE, 1299, and H460
were obtained from the American Type Culture Collec-
tion (Manassas, VA, USA). LK2 was obtained from the
Japanese Cancer Research Resources Bank (Tokyo, Japan),
SPC cells were obtained from the CCTCC (Chinese
Center of Typical Culture Conserve, Wuhan, P.R. China).
The cells were cultured in RPMI 1640 medium (Invitrogen,
Carlsbad, CA, USA) containing 10% fetal calf serum
(Invitrogen), 100 IU/ml penicillin (Sigma, St. Louis, MO,
USA), and 100 μg/ml streptomycin (Sigma).Western blot analysis
Total proteins from cell lines were extracted in lysis buffer
(Thermo Fisher Scientific, Rockford, IL, USA) and quanti-
fied using the Bradford method. Each extracted protein
sample (50 μg) was separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. After transferring to a
polyvinylidene fluoride membrane, the membrane was in-
cubated overnight at 4°C with the mouse monoclonal anti-
body against Oct4 (1:500, Santa Cruz Biotechnology),
KPNA2 (1:500, Santa Cruz Biotechnology), β-actin (1:1000,
Santa Cruz Biotechnology), or anti-lamin-B (1:500 Santa
Cruz Biotechnology). After incubation with peroxidase-
coupled anti-mouse IgG at 37°C for 2 h, the protein bands
were visualized using ECL (Pierce, Rockford, IL, USA) and
detected using the BioImaging Systems (UVP Inc., Upland,
CA, USA). The relative amounts of protein were calculated
with reference to the amount of β-actin protein.Quantitative real-time polymerase chain reaction (PCR)
Total cellular RNA was extracted from cells using the
RNeasy Mini kit from Qiagen (Hilden, Germany). Re-
verse transcription of 1 μg of RNA was performed using
a high-capacity cDNA RT kit (Applied Biosystems,
Foster City, CA, USA), following the manufacturer’s instruc-
tions. Quantitative real-time PCR was performed using a
SYBR Green PCR master mix (Applied Biosystems) in a total
volume of 20 μl on a 7900HT fast Real-Time PCR System
(Applied Biosystems). A dissociation step was performed to
generate a melting curve for confirmation of amplification
specificity. β-actin was used as the reference gene. The rela-
tive levels of gene expression were represented as △Ct =Ct
gene-Ct reference, and the fold change of gene expression
was calculated by the 2-△△Ct method. Experiments were
repeated in triplicate. The primer sequences were as
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CCAAG- 3′, KPNA2 reverse, 5′-ACACTGAGCCATCAC
CTGCAAT- 3′; Oct4 forward, 5′- CGCAAGCCCTCATT
TCAC-3′; Oct4 reverse, 5′- CATCACCTCCACCACCTG-
3′; β-actin forward, 5′-ATAGCACAGCCTGG ATAGCAA
CGTAC-3′, β-actin reverse, 5′-CACCTTCTACAATGAG
CTGCGTGTG- 3′.Immunofluorescence staining
Cells were placed into 96-well plain bottom plates, and
fixed in 4% formaldehyde, permeabilized in 0.5% Triton
X-100, and washed with PBS containing 1% of BSA
(FACS buffer). After incubation with primary antibodies
at 4°C overnight, the wells were washed with PBS three
times. Appropriate secondary antibodies were added and
incubated at 37°C for 30 min. The cells were then stained
with 4′, 6-diamidino-2-phenylindole (DAPI) for 15 min.
Specimens were examined using an epi-illumination fluores-
cence microscope BX50 (Olympus, Tokyo, Japan).Knockdown of Oct4 and KPNA2 expression with small
interfering RNA
Cells (1 × 104) were transfected with HiPerfect transfec-
tion reagent (Giagen, Germany), applying a combinationFigure 2 Kaplan–Meier survival curves. Kaplan–Meier curves for cumula
KPNA2 expression status (B, P = 0.013), and combined expression status of
calculated using log-rank comparisons.of two sequence-validated, and knockdown-warranted
siRNAs: KPNA2-siRNA (20 nM, each, 5′ -GCUCCUGC
AUCAUGAUGAUTT-3′ and 5′-AUCAUCAUGAUGCA
GGAGCTT-3′) and Oct4-siRNA (20 nM, each, 5′-CUG
GGACACAGUAGAUAGATT-3′ and 5′-UCUAUCUAC
UGU GUCCCAGTT-3′), according to the manufac-
turer’s instructions (GenePharma Co., Ltd, Germany).
After 96 h of treatment, the cells were split and re-
transfected with siRNAs to guarantee efficient KPNA2
and Oct4 knockdown. A commercial GAPDH-siRNA
served as a positive control (GenePharma). A green
fluorescent protein-tagged, NCsiRNA (GenePharma)
was used as an efficiency control and as a control for
unspecific side effects. At 72 h after transfection, cell
lysates were prepared for western blotting to deter-
mine the efficiency of gene expression ablation.Cell proliferation assay
Cell proliferation was assayed using a Cell Counting Kit-8
solution (Dojindo, Gaithersburg, MD, USA), according to
the manufacturer’s protocol. Briefly, cells were seeded at a
concentration of 2 × 103 cells/100 μl/well in 96-well cul-
ture plates and treated with 10 μl/well of Cell Counting
Kit-8H solution during the last 4 h of the culture. Thetive survival rates according to Oct4 expression status (A, P = 0.001),
Oct4/KPNA2 (C, P = 0.003) in NSCLC. Statistical differences were
Figure 3 (See legend on next page.)
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Figure 3 Loss of Oct4 or KPNA2 expression inhibits proliferation in tumor cells. Expression levels of Oct4 and KPNA2 were analyzed by
western blotting in a panel of lung cancer cell lines (A). Each bar represents the mean ± SD of three independent experiments. A549 and SPC
cells were treated with Oct4- or KPNA2-specific siRNAs for 72 h. Western blot of Oct4 and KPNA2 depletion efficiency in A549 and SPC cell lines
(B). Cell growth rate was determined by the CCK-8 assay, as described in Section 2. The data are mean ± SD of three independent experiments
(C). (Upper panel) A549 and SPC cells transduced with siRNAs for control, Oct4, or KPNA2 were subjected to a colony formation assay. (Lower
panel) Histogram quantification (D). Error bars indicate ± SD.*P < 0.05, **P < 0.01.
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a microplate reader (Model450, Bio-Rad, Hercules, CA,
USA).
Sphere formation assay
Cells (1 × 103) were seeded into 6-cm dishes and
maintained in growth medium. After 10 days, colonies
were fixed with 80% methanol and stained with Giemsa
(20 min.). Colonies were photographed and counted.
The number of colonies with more than 50 cells was
recorded.
Co-immunoprecipitation (CoIP)
Proteins were extracted with cellular lysis buffer. Equal
amounts of protein were incubated with the KPNA2
specific antibody immobilized onto protein G-beads for
1 h at 4°C with gentle rotation. Beads were washed ex-
tensively with lysis buffer, boiled, and microcentrifuged.
Proteins were detected with the anti-Oct4 antibody by
western blotting.
Statistical analysis
SPSS version 13.0 for Windows was used for all analyses.
The Chi-square test was used to compare positive stain-
ing rates between subgroups. Kaplan–Meier curves were
plotted for survival analysis, and a log-rank test was
performed based on the differences. The Student’s t-test
was used to compare other data. A P-value of < 0.05 was
considered statistically significant, and a P-value of
< 0.01 was considered strongly statistically significant.
Results
Overexpression of Oct4 and KPNA2 in NSCLC tissues
We investigated Oct4 and KPNA2 protein expression in
102 human NSCLC cancerous and precancerous tissue
samples by IHC. Overall, for both Oct4 and KPNA2,
positive immunostaining was only observed in the nuclei
of the cancer cells, whereas all the precancerous tissues
showed negative staining (Figure 1A–F). Among the 102
cancerous tissue samples, 29 (28.4%) showed positive
staining for Oct4, and 56 (54.9%) showed positive stain-
ing for KPNA2. Twenty-six (25.5%) cases showed both
Oct4 and KPNA2 positive staining; 43 (42.2%) cases
were negative for both Oct4 and KPNA2 staining; and
33 (32.3%) cases showed either Oct4 or KPNA2 positive
staining. The western blotting results agreed with theIHC results. The protein expressions of Oct4 and
KPNA2 in NSCLC tissues were significantly higher than
that of their paracancerous tissues (Figure 1G).
The expression of Oct4 and KPNA2 and their relation-
ships with clinicopathological characteristics are listed
in Table 1. The expression of Oct4 correlated with dif-
ferentiation (P = 0.002) and TNM stage (P = 0.003), and
the expression of KPNA2 correlated with histology
(P = 0.001) and differentiation (P = 0.045).
Correlation between Oct4 and KPNA2 expression in
NSCLC tissues
Oct4 and KPNA2 expressions were co-localized in the
same areas of the cell nuclei in some lung cancer speci-
mens (Figure 1H–K). Of the cases studied, 25.5%
showed both Oct4 and KPNA2 positive staining and
42.2% of the cases showed both Oct4 and KPNA2
negative staining. A cross analysis showed that Oct4
and KPNA2 expressions were significantly correlated
(P = 0.000, Table 2).
Association with survival
We analyzed the relationship of Oct4 and KPNA2 ex-
pressions with the overall survival rate. A multivariate
survival analysis was performed with a Cox regression
model for each predictor of prognosis using the IHC re-
sults. We found that the overall survival rate was signifi-
cantly lower in patients with Oct4 or KPNA2 positive
expression than in patients with Oct4 or KPNA2 nega-
tive expression (P < 0.01, Figure 2).
Loss of Oct4 or KPNA2 expression inhibits proliferation in
tumor cells
Expression levels of Oct4 and KPNA2 were analyzed
by western blotting in a panel of lung cancer cell lines
(Figure 3A). The levels of Oct4 and KPNA2 were both
higher in A549 and SPC cells than in the other cell
lines. To explore whether Oct4 and KPNA2 play a role
in cancer cell growth, we employed an RNA interfer-
ence approach to knockdown Oct4 and KPNA2 ex-
pression in both A549 and SPC cell lines. The Oct4
and KPNA2 expression levels were unchanged upon
transient transfection with the negative control siRNA,
whereas Oct4- or KPNA2-specific siRNA significantly
suppressed protein expression levels in the A549 and
SPC cell lines (Figure 3B). Upon Oct4 or KPNA2
Figure 4 (See legend on next page.)
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Figure 4 Oct4 interacts with KPNA2 in vitro. A549 and SPC cells were treated with KPNA2-specific siRNA for 72 h. The nucleus and cytoplasm
protein expression levels of Oct4 and KPNA2 were analyzed by western blotting (A). Expression of β-actin and lamin-B served as loading controls
for the cytosolic and the nuclear fractions, respectively. Real-time PCR analyses of KPNA2 and Oct4 mRNA expression in cancer cells (B).
Immunofluorescence staining showing the localization of Oct4 and KPNA2 in A549 and SPC cancer cell lines (C). Relative fluorescence levels of
Oct4 were measured in cells after KPNA2 siRNA treatment. Relative fluorescence ratios of Oct4:DAPI are indicated as the mean ± SD for four fields
for siNC and siKPNA2 (D). *P < 0.05. Co-immunoprecipitation of KPNA2 and Oct4 in A549 and SPC cells (E): whole cell lysates were
immunoprecipitated with KPNA2 antibody and analyzed by western blotting with the anti-Oct4 antibody.
Li et al. Journal of Translational Medicine 2013, 11:232 Page 9 of 11
http://www.translational-medicine.com/content/11/1/232siRNA transfection, A549 cells displayed reduced growth
rates compared with the negative control (Figure 3C).
Similar to A549 cells, knockdown of Oct4 or KPNA2 ex-
pression also reduced the growth rate of SPC cells
(Figure 3C). We used colony formation assays as an in-
dependent method to validate the antiproliferative ef-
fects of Oct4 or KPNA2 inhibition in lung cancer cells.
Oct4- or KPNA2-targeting siRNAs led to a clear re-
duction of the colony formation capacity of A549 and
SPC lung cancer cell lines compared with control
siRNA-treated cells (Figure 3D). These loss-of-function
studies demonstrated that the Oct4 and KPNA2 siRNAs
could inhibit tumor cell proliferation compared with the
control.
Oct4 interacts with KPNA2 in vitro
To explore whether KPNA2 contributes to Oct4 nuclear
translocation in lung cancer, we extracted nuclear and
cytoplasmic proteins, respectively, after 72 h of KPNA2
siRNA treatment with Thermo Scientific NE-PER Nu-
clear and Cytoplasmic Extraction Reagents. Western
blotting analysis revealed that knockdown of KPNA2 de-
creased the nucleoprotein levels of Oct4 (Figure 4A).
Furthermore, both KPNA2 and Oct4 mRNA expression
levels were reduced after 72 h of KPNA2 siRNA treat-
ment, as observed by real-time PCR (Figure 4B). Double
immunofluorescence analysis was performed, and co-
localization of Oct4 and KPNA2 was observed in A549
and SPC cell lines. The proportion of cells with significant
nuclear Oct4 signals was reduced significantly in the
KPNA2 knockdown cell group, compared with siNC cells.
Cells with significant cytoplasmic Oct4 signals were ob-
served in the KPNA2 knockdown group, but not the control
group (Figure 4C-D). Co-immunoprecipitation revealed that
KPNA2 interacts with Oct4 in lung cancer cell lines
(Figure 4E).
Discussion
In this study, we investigated the expression pattern and
biological role of the transcription factor Oct4 and
transport factor KPNA2 in 102 human NSCLC samples.
Our results demonstrated that Oct4 and KPNA2 protein
expression in lung cancer tissues is higher compared
with corresponding normal lung tissue. We found a sig-
nificant correlation between Oct4 upregulation and bothdifferentiation and TNM stage. The expression of
KPNA2 correlates with histology and differentiation. Al-
though Oct4 and KPNA2 were expressed independently
in some cases, they were more often co-localized to the
same area. We also found that Oct4 and KPNA2 expres-
sions were significantly correlated in human NSCLC tis-
sues. This suggested that Oct4 and KPNA2 have an
interaction in NSCLC. In addition, we demonstrated that
Oct4 and KPNA2 upregulation correlated with a lower
survival rate in NSCLC patients. This indicates that
Oct4 and KPNA2 could represent novel biomarkers for
distinguishing cancer from noncancerous lesions. At the
same time, we found that Oct4 and KPNA2 expressions
were co-positively correlated with shorter survival of
NSCLC patients, compared with Oct4 and KPNA2 co-
negative expression or Oct4 and KPNA2 single posi-
tive expression. Thus, combined analysis of Oct4 and
KPNA2 expression in NSCLS was more informative
than the analysis of either gene singly.
To validate the potential role of Oct4 and KPNA2 in
lung cancer development, we employed siRNAs to
knockdown Oct4 and KPNA2 expression in A549 and
SPC cell lines. We found an impaired proliferation cap-
acity and colony formation ability in both A549 and SPC
cells after Oct4 or KPNA2 knockdown. These results
suggest that Oct4 and KPNA2 expression were signifi-
cantly correlated in lung cancer cells. High expression of
these two proteins could promote the proliferation of
lung cancer cells. Co-immunoprecipitation revealed that
KPNA2 interacts with Oct4 in lung cancer cell lines.
Moreover, knockdown of KPNA2 expression decreased
the mRNA and nucleoprotein levels of Oct4. Double im-
munofluorescence analysis revealed that nuclear Oct4
signals were significantly reduced in the KPNA2 knock-
down group.
The transcription factor Oct4 plays significant roles in
maintaining pluripotency and self-renewal of embryonic
stem cells and adult stem/progenitor cells anchored in a
number of tissues [18,19]. Oct4 alone can induce
pluripotency in mouse adult neural stem cells [20].
Furthermore, Oct4 is an important determinant for the
malignant potential of tumor cells and is accordingly
not expressed in healthy and differentiated tissue [21].
The Oct4 transcript can be detected in human embryonic
carcinomas, testicular germ cell tumors, and seminomas
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would lead to the loss of the self-renewal and proliferating
capacities and result in CSC-like apoptosis of cancer cells
[25]. Our results contribute to the growing body of evi-
dence that implicates Oct4 as a multifunctional factor in-
volved in stem cell self-renewal and differentiation, as well
as tumorigenesis and tumor progression. Recently, Oct4A
was observed to contain a conserved nuclear localization
signal (NLS), RKRKR, in its POU DNA binding domain
[26]. It is recognized by transport receptors that carry it
from the cytoplasm to the nucleus. Tumorigenesis and
tumor progression are associated with dysfunction of the
nuclear transport machinery.
Karyopherin-α acts as a classical NLS receptor and
mammalian cells have multiple Karyopherin-α genes
that are classified into three subtypes that are differen-
tially expressed in different tissues [27-29]. A previous
study indicated that KPNA2 is mainly expressed in un-
differentiated ES cells [15]. Overexpression of KPNA2
caused persistent expression of pluripotency marker
genes, such as Oct4, in the absence of maintenance signals,
and suppressed neural differentiation [15]. Upregulation of
KPNA2 expression has been implicated in several human
cancers, including prostate cancer, esophageal squamous
cell carcinoma, lung cancer, breast cancer, and infiltrative
astrocytomas [17,30-34]. In breast tumor MCF7 cells,
Oct4 expression was further increased by KPNA2
overexpression [22]. In this study, we demonstrated
that knocking down KPNA2 expression decreased the
mRNA and nucleoprotein levels of Oct4. This indi-
cated that KPNA2-associated Oct4 downstream signal-
ing may contribute to the malignant phenotype of
human lung cancer cells. Oct4 transcription could be
influenced by gradually varying KPNA2 expression
levels. KPNA2 silencing could therefore decrease the
nuclear translocation of Oct4 and suppress the prolif-
erative capacity of lung cancer cells. Thus, Oct4 may
be one of the target proteins of nuclear transport re-
ceptor KPNA2 in lung cancer cells. However, recipro-
cal effects between KPNA2 expression and Oct4
should be addressed in future studies.
Conclusions
Our study demonstrated that Oct4 and KPNA2 are
overexpressed in NSCLC and that this overexpression cor-
relates with lung cancer progression. Oct4 and KPNA2
expression levels are significantly correlated. Both Oct4
and KPNA2 promote lung cancer proliferation. Oct4 nu-
clear localization may be mediated by its interaction with
KPNA2 in lung cancer cells. KPNA2 might be a useful
therapeutic target of NSCLC.
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